Clinical GuidelineGuidelinePatient Education

ASTRO guideline defines radiation pathways across bladder cancer settings

Practical radiation oncology (PubMed)Sep 15, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

An ASTRO clinical practice guideline recommends multidisciplinary evaluation and outlines evidence-based radiation approaches for bladder preservation, postoperative locoregional control, and palliation in localized, node-positive, metastatic, or symptomatic bladder cancer.

What NurseJet pulled from the source

For selected patients with cT2-4aN0M0 muscle-invasive disease, the guideline describes trimodal therapy as an alternative to radical cystectomy and recommends concurrent radiosensitizing systemic therapy. It also addresses conditional postoperative radiation and bladder-directed radiation for local control or palliation in noncurative settings.

Why this matters for nurses

Oncology nurses coordinate treatment preparation, systemic-therapy support, symptom assessment, and follow-up across multimodal bladder-cancer care. The guideline reinforces that radiation decisions depend on stage, treatment intent, pathology, and multidisciplinary review.

Bedside takeaway

Anchor bladder-cancer radiation teaching to documented stage, treatment intent, and the multidisciplinary plan.

Key takeaways

Multidisciplinary evaluation is encouraged for all patients with bladder cancer being considered for radiation therapy.
The guideline recommends intensity-modulated radiation therapy with daily image guidance and provides target-coverage and normal-tissue dose guidance.
Adjuvant radiation is conditionally recommended for selected high-risk pathologic findings after cystectomy, while bladder-directed radiation is recommended for local control or palliation in selected noncurative settings.

Practice implications

Verify the documented treatment intent and concurrent systemic-therapy plan, reinforce the radiation-oncology team's preparation and monitoring instructions, and escalate treatment concerns through the local oncology pathway.

Limitations & cautions

Abstract-only summary. The abstract reports selected recommendations but not the full evidence tables, recommendation grades, dose details, contraindications, or patient-selection criteria; clinicians should consult the complete guideline.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Practical radiation oncology (PubMed)

Practical radiation oncology (PubMed). Radiation Therapy for Bladder Cancer: An ASTRO Clinical Practice Guideline.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42744092/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Breast Cancer Research and Treatment (PubMed)Sep 22, 2026Systematic Review

A systematic review and meta-analysis found that ovarian function recovery after chemotherapy was limited among premenopausal women with breast cancer and increased over time, with older age and longer chemotherapy associated with lower recovery odds.

Oncology L&D / OBAI summaryReview source

Systematic ReviewResearchPatient EducationWorkflowAI summary · original source linked below

Across 34 studies including 10,216 women, pooled recovery probabilities were 30.4% at 12 months, 38.5% at 24 months, and 43.4% at 60 months. The pooled mean time to recovery was 12.3 months, and the wide confidence intervals show substantial uncertainty around longer-term estimates.

Key takeaways

Older age was associated with lower odds of ovarian function recovery, with a pooled odds ratio of 0.25.
Longer chemotherapy duration was also associated with lower recovery odds, with a pooled odds ratio of 0.68.
Pretreatment anti-Müllerian hormone appeared favorable in individual studies, but the pooled association was not statistically significant.

Why this matters on shift

Oncology nurses often identify fertility concerns, prepare patients for treatment effects, and coordinate referrals. The findings reinforce the importance of discussing reproductive risk and established fertility-preservation options before cancer-directed therapy begins.

Bedside takeaway

Surface reproductive goals before chemotherapy and help complete timely fertility-preservation referrals through the approved oncology pathway.

Nursing implications

Ask about reproductive goals before treatment when appropriate, document concerns, and route timely referrals through the oncology team's fertility-preservation pathway. Present recovery estimates as pooled probabilities rather than predictions for an individual patient.

Limitations & cautions

The studies varied in populations, treatments, and definitions of ovarian recovery. Confidence intervals were wide, especially at 60 months, and the abstract does not establish which fertility-preservation strategy is best for an individual patient.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Breast Cancer Research and Treatment (PubMed). Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer: a systematic review and meta-analysis.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of Neurology (PubMed)Sep 20, 2026Systematic Review

A systematic review characterized cancer-associated coagulopathy stroke as an underrecognized ischemic stroke mechanism linked to advanced cancer, early recurrence, and poor outcomes.

Emergency OncologyAI summaryReview source

Systematic ReviewResearchMedication SafetyWorkflowAI summary · original source linked below

The qualitative review included 82 studies. Cancer-associated coagulopathy stroke occurred predominantly within six months of cancer diagnosis, most often with advanced or metastatic adenocarcinoma; D-dimer was the biomarker most consistently associated with recurrence and mortality, and reported 30-day mortality ranged from 25% to 50%.

Key takeaways

Lung and pancreatic adenocarcinomas were the histologic subtypes most frequently associated with cancer-related coagulopathy stroke.
Multiple infarcts across more than two vascular territories were a characteristic imaging pattern described in the review.
Low-molecular-weight heparin and direct oral anticoagulants were commonly used for secondary prevention, but the review did not establish one optimal antithrombotic strategy.

Why this matters on shift

Neuro and oncology nurses may be first to recognize a new focal deficit or recurrent neurologic change in a patient with active cancer. The review highlights a high-risk stroke mechanism that requires rapid assessment while leaving treatment selection to individualized multidisciplinary evaluation.

Bedside takeaway

Escalate new neurologic deficits immediately and communicate the patient's cancer and antithrombotic context to the stroke team.

Nursing implications

Treat any new focal neurologic deficit as an emergency, document onset and progression precisely, and promptly communicate active or metastatic cancer, recent cancer diagnosis, coagulation results, and current antithrombotic therapy to the stroke team. Follow facility stroke and anticoagulation protocols and provider orders.

Limitations & cautions

The review synthesized heterogeneous studies qualitatively and did not report a pooled treatment comparison. Biomarkers other than D-dimer had limited specificity, and the abstract does not support choosing one anticoagulant or screening strategy.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of Neurology (PubMed). Stroke secondary to cancer-associated coagulopathy: a systematic review.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Supportive Care in Cancer (PubMed)Sep 20, 2026Systematic Review

A qualitative systematic review found that families of children with cancer experienced sustained financial strain from direct and indirect costs, lost income, and gaps in insurance or social support.

Oncology PedsAI summaryReview source

Systematic ReviewResearchPatient EducationWorkflowAI summary · original source linked below

The review synthesized 14 moderate-to-high-quality studies involving 524 participants, primarily parents, across seven countries. Families described debt, reduced living standards, psychosocial effects, and long-term vulnerability; financial assistance and reorganizing family life often provided only partial relief.

Key takeaways

Financial toxicity accumulated from medical expenses, indirect costs, employment disruption, and inadequate insurance or social support.
The burden extended beyond treatment and affected household stability, living standards, and psychosocial wellbeing.
Families used financial assistance and major changes to work and daily life, but these strategies often did not fully relieve the burden.

Why this matters on shift

Oncology and pediatric nurses may hear practical barriers before they appear in formal screening. The review supports treating cost, work disruption, travel, and access to assistance as parts of family-centered supportive care rather than assuming families will raise them independently.

Bedside takeaway

Screen early for treatment-related financial strain and route concerns through the pediatric oncology support pathway.

Nursing implications

Ask families whether treatment-related costs, travel, missed work, or access to basic needs are creating difficulty, document the concern, and connect them with the oncology social worker, financial navigator, or other approved support pathway early.

Limitations & cautions

This was a qualitative synthesis rather than an intervention study, so it does not estimate prevalence or prove that a specific support program improves outcomes. Most participants were parents, and experiences may differ across health systems and family structures.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Supportive Care in Cancer (PubMed). Financial toxicity among families of children with cancer: a qualitative systematic review and meta-aggregation.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

Ovarian function recovery after breast cancer chemotherapy remained limited

Cancer-associated coagulopathy stroke carried high early recurrence and mortality risk

Pediatric cancer costs created sustained financial strain across 14 qualitative studies